Adoptive Immunotherapy

Imaging the Future of Therapeutics

Adoptive Immunotherapy and Molecular Imaging

Adoptive immunotherapy is an exciting new area of oncology therapeutic development, and one uniquely suited to molecular imaging. Fundamentally it is the ability of molecular imaging that allows for a wide range of cells can be tracked. We continue to lead in the in-vivo immune cell therapeutics imaging space through its capabilities in in-vitro cell labeling and in-vivo cell tracking by a variety of modalities.

While much of the research today is focused on rodent oncology models, BioLaurus continues to expand its capabilities in performing cell trafficking studies in larger animals and non-human primates.

It’s in the Details…

Study design is critical in this field, as the coordination of in-vitro cell isolation, activation, and labeling are in play, along with with in-vivo injection and imaging. Plenty of moving parts to manage.

At the core of design considerations are the varios phases of in-vivo tracking – early events in the first 1-24 hours, or long term (days to weeks). Early events are often best captured by radiolabeling cells, often with Indium – this technology is biocompatible, non-immunogenic, FDA-approved and widely adaptable to all animals and translation clinical research. A rare solution for this difficult science. Fluorescence cell labeling is an option in mouse models. For long-term tracking (more than 8 days) typically requires the transfection of cells with a reporter gene. Often immune therapy studies include hematology analysis, flow cytometry, clinical chemistry and arms for immunohistology. We know this sounds like a lot of options – contact us and we can help design something that meets your specific needs.

Learn more about our adoptive immunotherapy studies.